1,049 reports of this reaction
3.7% of all CEFEPIME HYDROCHLORIDE reports
#4 most reported adverse reaction
PYREXIA is the #4 most commonly reported adverse reaction for CEFEPIME HYDROCHLORIDE, manufactured by Sagent Pharmaceuticals. There are 1,049 FDA adverse event reports linking CEFEPIME HYDROCHLORIDE to PYREXIA. This represents approximately 3.7% of all 28,358 adverse event reports for this drug.
Patients taking CEFEPIME HYDROCHLORIDE who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is moderately reported among CEFEPIME HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to pyrexia, the following adverse reactions have been reported for CEFEPIME HYDROCHLORIDE:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 1,049 FDA reports for CEFEPIME HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 3.7% of all adverse event reports for CEFEPIME HYDROCHLORIDE, making it a notable side effect.
If you experience pyrexia while taking CEFEPIME HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.